Steady decline, page-10

It's a spec biotech stock.
This is how it rolls.
The current major hurdle is patient enrolment.
Nothing material is going to happen to the SP until we get over that and in the meantime holders will lose patience and decide there's somewhere better for their capital.
Anyone who got in at the bottom and got out at the top are already sipping cocktails on their yachts somewhere off the Amalfi Coast.
The longer this trial takes the lower the SP is likely to go which is a great buying opportunity.
I bought in at IPO at 17c and kept buying down to 1.5c.
I bought more OA's recently at 3.6c.
When successful trial data is eventually released make sure you're buckled up.
DYOR.